Bacteriotherapy for preventing recurrent upper respiratory infections in children: a real-world experience
- PMID: 29989557
- DOI: 10.5604/01.3001.0012.0482
Bacteriotherapy for preventing recurrent upper respiratory infections in children: a real-world experience
Abstract
Background Recurrent upper respiratory infections (RURI) constitute a social problem for both their pharmaco-economic impact and the burden for the family. Bacteriotherapy could be an interesting preventive option. Objective The aim of this study was to evaluate the preventive effects of RURI in children. Design The study was designed as spontaneous, and was conducted in real-life seting. Globally, 80 children (40 males, mean age 5.26 (2.52) years) with RURI were enrolled. Children were treated with Streptococcus salivarius 24SMB and Streptococcus oralis 89a: nasal spray 2 puffs per nostril twice/day for a week for 3 monthly courses. Number of URI, and school and work absences were evaluated and compared with the past year. Results Bacteriotherapy significantly halved the mean number of URI episodes being 5.98 (2.30) in the past year and 2.75 (2.43) after the treatment (p<0.0001). Bacteriotherapy also induced an over 35% reduction both in the number of school days and in the number of working days missed per month from 4.50 (2.81) to 2.80 (3.42) and from 2.33 (2.36) to 1.48 (2.16) respectively (p<0.0001). Conclusions This and real-life study provides the first evidence that Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray could be effective in preventing RURI in children.
Keywords: Streptococcus oralis89a; Streptococcus salivarius 24SMB; bacteriotherapy; children; nasal spray; recurrent upper respiratory infections.
Similar articles
-
Bacteriotherapy in children with recurrent upper respiratory tract infections.Eur Rev Med Pharmacol Sci. 2019 Mar;23(1 Suppl):39-43. doi: 10.26355/eurrev_201903_17347. Eur Rev Med Pharmacol Sci. 2019. PMID: 30920639
-
Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for treatment of upper respiratory tract infections in children: a pilot study on short-term efficacy.Ital J Pediatr. 2020 Apr 3;46(1):42. doi: 10.1186/s13052-020-0798-4. Ital J Pediatr. 2020. PMID: 32245500 Free PMC article. Clinical Trial.
-
Oral bacteriotherapy in children with recurrent respiratory infections: a real-life study.Acta Biomed. 2020 Feb 17;91(1-S):73-76. doi: 10.23750/abm.v91i1-S.9230. Acta Biomed. 2020. PMID: 32073565 Free PMC article.
-
Local Bacteriotherapy - a promising preventive tool in recurrent respiratory infections.Expert Rev Clin Immunol. 2020 Nov;16(11):1047-1052. doi: 10.1080/1744666X.2021.1833720. Epub 2020 Oct 15. Expert Rev Clin Immunol. 2020. PMID: 33022191 Review.
-
An overview on upper respiratory tract infections and bacteriotherapy as innovative therapeutic strategy.Eur Rev Med Pharmacol Sci. 2019 Mar;23(1 Suppl):27-38. doi: 10.26355/eurrev_201903_17345. Eur Rev Med Pharmacol Sci. 2019. PMID: 30920638 Review.
Cited by
-
Bacterial salivary microbiome associates with asthma among african american children and young adults.Pediatr Pulmonol. 2019 Dec;54(12):1948-1956. doi: 10.1002/ppul.24504. Epub 2019 Sep 9. Pediatr Pulmonol. 2019. PMID: 31496123 Free PMC article.
-
Prevention of recurrent respiratory infections : Inter-society Consensus.Ital J Pediatr. 2021 Oct 25;47(1):211. doi: 10.1186/s13052-021-01150-0. Ital J Pediatr. 2021. PMID: 34696778 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous